Blood DNA methylation, nevi number, and the risk of melanoma

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 480-487

  Pergoli, Laura ^a   Favero, Chiara ^a   Pfeiffer, Ruth M ^d   Tarantini, Letizia ^a   Calista, Donato ^c   Cavalleri, Tommaso ^a   Angelici, Laura ^a   Consonni, Dario ^b   Bertazzi, Pier A ^a,b   Pesatori, Angela C ^a,b   Landi, Maria T ^d   Bollati, Valentina ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c BUFALINI HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cutaneous malignant melanoma; Methylation; Nevi; Pyrosequencing

Indexed keywords

BISULFITE; CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INTERCELLULAR ADHESION MOLECULE 1; MELANOCORTIN 1 RECEPTOR; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PLACENTA PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SYNCYTIN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; VIRUS ENVELOPE PROTEIN;

ALU GENE; ARTICLE; CANCER RISK; CDK4 GENE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CUTANEOUS MELANOMA; DNA METHYLATION; DYSPLASTIC NEVUS; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GERMLINE MUTATION; HERV W GENE; HTERT GENE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LINE 1 GENE; MAJOR CLINICAL STUDY; MALE; MC1R GENE; MISMATCH REPAIR; MLH1 GENE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; P14 GENE; P16 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PYROSEQUENCING; SKIN MANIFESTATION; STATISTICAL ANALYSIS; TNF ALPHA GENE; ALU SEQUENCE; BLOOD; CASE CONTROL STUDY; CYTOLOGY; GENETICS; LONG INTERSPERSED REPEAT; MELANOMA; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; MUTATION; NEVUS; PATHOPHYSIOLOGY; RISK FACTOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALU ELEMENTS; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE PRODUCTS, ENV; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES, MONONUCLEAR; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; MELANOMA; MULTIVARIATE ANALYSIS; MUTATION; NEVUS; NUCLEAR PROTEINS; PREGNANCY PROTEINS; RECEPTOR, MELANOCORTIN, TYPE 1; RISK FACTORS; TELOMERASE; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 84926112298     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000112     Document Type: Article

References (48)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-185.
2. Boniol M, Sallin J, Doré JF. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2002;94:1902-1903.
3. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-1491.
4. Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003;120:217-223.
5. Bressac-de-Paillerets B, Avril MF, Chompret A, Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002;84:67-74.
6. Hill VK, Gartner JJ, Samuels Y, Goldstein AM. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013;14:257-279.
7. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-452.
8. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a populationbased sample. J Natl Cancer Inst 2005;97:1507-1515.
9. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 2011;43:1108-1113.
10. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41:920-925.
11. Law MH, Montgomery GW, Brown KM, Martin NG, Mann GJ, Hayward NK, et al. Meta-analysis combining new and existing data sets confirms that the TERT-CLPTM1L locus influences melanoma risk. J Invest Dermatol 2012;132:485-487.
12. Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 2013;50:264-270.
13. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480:99-103.
14. Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012;7:e35295.
15. Cropley JE, Martin DI, Suter CM. Germline epimutation in humans. Pharmacogenomics 2008;9:1861-1868.
16. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 2009;46:793-802.
17. Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006;38:1178-1183.
18. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007;129:879-890.
19. Hansmann T, Pliushch G, Leubner M, Kroll P, Endt D, Gehrig A, et al. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet 2012;21:4669-4679.
20. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006;66:6546-6552.
21. Landi MT, Goldstein AM, Tsang S, Munroe D, Modi W, Ter-Minassian M, et al. Genetic susceptibility in familial melanoma from northeastern Italy. J Med Genet 2004;41:557-566.
22. Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng T, et al. XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. Br J Cancer 2004;90:497-502.
23. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007;96:1879-1887.
24. Tsoka S, Ainali C, Karagiannis P, Josephs DH, Saul L, Nestle FO, Karagiannis SN. Toward prediction of immune mechanisms and design of immunotherapies in melanoma. Crit Rev Biomed Eng 2012;40:279-294.
25. Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 2007;356:697-705.
26. Pogribny IP, Beland FA. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 2009;66:2249-2261.
27. Landi MT, Baccarelli A, Tarone RE, Pesatori A, Tucker MA, Hedayati M, Grossman L. DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst 2002;94:94-101.
28. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
29. Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res 2007;67:876-880.
30. Li L, Choi JY, Lee KM, Sung H, Park SK, Oze I, et al. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol 2012;22:384-394.
31. Gao L, Smit MA, Van Den Oord JJ, Goeman JJ, Verdegaal EM, Van Der Burg SH, et al. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res 2013;26:542-554.
32. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150:1135-1146.
33. Hyland PL, Burke LS, Pfeiffer RM, Mirabello L, Tucker MA, Goldstein AM, Yang XR. LINE-1 methylation in peripheral blood and the risk of melanoma in melanoma-prone families with and without CDKN2A mutations. Melanoma Res 2013;23:55-60.
34. Sigalotti L, Fratta E, Parisi G, Coral S, Maio M. Epigenetic markers of prognosis in melanoma. Methods Mol Biol 2014;1102:481-499.
35. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.
36. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-99.
37. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci 2008;13:5094-5107.
38. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006;25:409-416.
39. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010;102:639-644.
40. Lin X, Zheng W, Liu J, Zhang Y, Qin H, Wu H, et al. Oxidative stress in malignant melanoma enhances tumor necrosis factor-α secretion of tumorassociated macrophages that promote cancer cell invasion. Antioxid Redox Signal 2013;19:1337-1355.
41. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med 2006;79:123-130.
42. Goldstein AM, Tucker MA. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 2013;22:528-532.
43. Nan H, Du M, De Vivo I, Manson JE, Liu S, McTiernan A, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 2011;71:6758-6763.
44. Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ, De Vivo I. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009;129:415-421.
45. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-961.
46. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-959.
47. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alphaactivated vascular endothelium under flow. Blood 2005;106:584-592.
48. Alegria-Torres JA, Baccarelli A, Bollati V. Epigenetics and lifestyle. Epigenomics 2011;3:267-277.